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Abstract
Background: Inflammatory process results in lung injury that may lead to pulmonary fibrosis (PF).
Here, we described PF in mice infected with H5N1 virus.
Methods: Eight-week-old BALB/c mice were inoculated intranasally with 1 × 101 MID50 of A/
Chicken/Hebei/108/2002(H5N1) viruses. Lung injury/fibrosis was evaluated by observation of
hydroxyproline concentrations, lung indexes, and histopathology on days 7, 14, and 30
postinoculation.
Results: H5N1-inoculated mice presented two stages of pulmonary disease over a 30-d period
after infection. At acute stage, infected-mice showed typical diffuse pneumonia with inflammatory
cellular infiltration, alveolar and interstitial edema and hemorrhage on day 7 postinoculation. At
restoration stage, most infected-mice developed PF of different severities on day 30
postinoculation, and 18% of the survived mice underwent severe interstitial and intra-alveolar
fibrosis with thickened alveolar walls, collapsed alveoli and large fibrotic areas. The dramatically
elevated hydroxyproline levels in H5N1-infected mice showed deposition of collagen in lungs, and
confirmed fibrosis of lungs. The dry lung-to-body weight ratio was significantly increased in infected
group, which might be associated with the formation of PF in H5N1-infected mice.
Conclusion: Our findings show that H5N1-infected mice develop the typical PF during restoration
period, which will contribute to the investigation of fibrogenesis and potential therapeutic
intervention in human H5N1 disease.
Introduction
Human infections with avian H5N1 influenza virus from
birds have occurred successively since the first case was
reported in Hong Kong, 1997, which demonstrated that
an avian influenza virus could cross the species barrier to
infect humans and it is possible that avian influenza virus
mutates to be able to transmit among humans [1-3]. As of
12 December 2008, the World Health Organization
(WHO) reported that H5N1 virus had caused 390 human
infections with 246 people deaths, representing a mortal-
ity rate over 60% [4]. WHO has warned of a substantial
risk of pandemic of avian influenza in the near future.
Human H5N1 infection is characterized by a severe influ-
enza syndrome, including fever, cough, shortness of
breath, and radiological evidence of pneumonia [5,6].
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Almost all patients have clinically apparent pneumonia,
and death ensues within 9 or 10 days on average after the
onset of illness. Most patients die of progressive respira-
tory failure that is believed to be associated with acute res-
piratory distress syndrome (ARDS) [1,7]. ARDS is a
common, devastating clinical syndrome of acute lung
injury with high mortality ranging from 40% to 60%
[8,9]. Pathological findings show that 64% of ARDS
patients may have pulmonary fibrosis (PF) during conva-
lescence [10]. Owing to the damage of architecture and
loss of functional capillary units of the lung, Idiopathic
pulmonary fibrosis (IPF) in human can lead to respiratory
failure within a few years following diagnostic confirma-
tion, and may correlate with an increased risk of death
[11]. PF results as a consequence of many types of severe
lung injury and is almost always associated with an
inflammatory reaction [12,13]. Some virus infections,
such as severe acute respiratory syndrome (SARS) caused
by a novel coronavirus, can induce the typical ARDS and
PF, and most patients eventually die [14,15]. Also, it is
possible that patients infected with H5N1 viruses may suf-
fer from PF as a result of ARDS.
Moreover, if the pandemic outbreak of avian H5N1 influ-
enza in human occurs, as a major consequence of ARDS
induced by H5N1 virus, PF may prove to be a thorny
sequela for treatment. Because clinical experience with
avian H5N1 disease in humans is limited and patients
mostly die during early period of pneumonia, we know
little about pathological changes in the lung during con-
valescence. Laboratory animal can provide considerable
insight into the pathogenesis of the complex process of
fibrosis in the lung. Our previous study showed that
H5N1 virus could induce the typical ARDS in mice, which
was characterized by about 80% mortality, progressive
hypoxemia, and pulmonary inflammatory cellular infil-
tration, alveolar and interstitial edema and hemorrhage
[16]. In this study, we used a mouse model to investigate
the pathological changes at restoration stage induced by
H5N1 viral infection, to provide basis for future investiga-




The virus used was isolated from chicken in the Hebei
Province of China in January 2002, and identified as avian
influenza A H5N1 virus by means of hemagglutination
inhibition (HI) and neuraminidase inhibition tests. The
isolate was designated as A/Chicken/Hebei/108/2002
(H5N1) (Chicken/HB/108). The complete genome
sequences (DQ343152, DQ349116, DQ351860,
DQ351861, DQ351866, DQ351867, DQ351872, and
DQ351873) of the virus can be obtained from GenBank.
The virus caused 100% (8 of 8) mortality of 4-wk-old spe-
cific pathogen-free (SPF) chicken within 2 days after intra-
venous infection with 0.2 ml of infectious allantoic fluid
at 1:10 dilution. This virus belongs to a highly pathogenic
avian influenza virus, according to the criteria of viral vir-
ulence [17]. Our previous studies showed that this virus
was highly lethal to mice and could cause typical ARDS in
mice [16]. The virus was propagated in the allantoic cavi-
ties of 10-day-old embryonated SPF chicken eggs at 37°C
for 32 h, and third-passage virus was gradient purified and
stored at -80°C until use. All manipulations of live viruses
were conducted in biosafety level 3+ (BSL-3+) facilities.
Animals and inoculation with virus
Eight-wk-old female SPF BALB/c mice with body weight of
17-18 g were purchased from Beijing Laboratory Animal
Research Center (Beijing, People's Republic of China),
and housed in microisolator cages ventilated under nega-
tive pressure with HEPA-filtered air. During the experi-
ments, mice were given food and water ad lib.
Our previous study showed that the dose of 1 × 101 mouse
infectious doses (MID50) of Chicken/HB/108 H5N1 virus
was optimal for the observation of PF. At this dosage, the
course of the H5N1 disease was slightly prolonged, and
infected mice presented obvious lung injury and PF over a
30-d time period. When animals were infected with a
higher dose of 1 × 102 MID50, more than 80% mice died,
but with a lower dose of 1 × 100 MID50, the lung injury
and PF were not demonstrated. Therefore, in this experi-
ment, mice were inoculated intranasally (50 μl) with 1 ×
101 MID50 of Chicken/HB/108 H5N1 virus diluted in ster-
ile saline after lightly anesthetized with diethyl ether. Mice
in control group were inoculated with an equivalent dilu-
tion (50 μl) of noninfectious allantoic fluid. All manipu-
lations were performed under BSL-3+ laboratory
conditions. Animal experiments were conducted accord-
ing to the established guidelines and approved by the Ani-
mal Care Committee of China Agricultural University
(Beijing, People's Republic of China).
Experimental protocols
Two types of experiments were carried out in this study.
The first experiment was to investigate the mortality, clin-
ical signs, and the presence and severity of PF in H5N1-
infected mice over a 30-d time period. In this experiment,
70 mice were divided randomly into two groups. H5N1-
infected group of 50 mice was inoculated with H5N1
virus, and control group of 20 mice received the noninfec-
tious allantoic fluid, as described above. The animals' gen-
eral behavior and clinical signs, including the food intake,
body weight, inactivity, anal temperature (measured with
an infrared thermometer) and mortality were monitored
daily in each group for 30 days. To observe the food
intake, the mice were housed individually, on grids in
boxes which were changed twice/week. They wereRespiratory Research 2009, 10:107 http://respiratory-research.com/content/10/1/107
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weighed daily and their food intake was measured by
offering daily known weights of food and separating and
weighing any leftover food in the box at each change. On
day 30 after infection, all the mice survived were sacrificed
and the whole lungs were removed to assess the degree of
PF.
In the second experiment, we characterized the develop-
ment of lung injury and PF of mice after H5N1 viral infec-
tion. Mice were divided randomly into two groups with
40 mice each, as described in experiment 1. Since about
60% mice died between day 6 and day 8 postinoculation
(p.i.), larger groups (40 per group) of mice were used.
Virus inoculation was the same as this used in experiment
1. Four mice of each group were weighed and euthanized
on days 3, 7, 14, and 30 p.i. The whole lungs were
removed. Left lobes of lungs were fixed in buffered 10%
formalin and embedded in paraffin for histopathological
evaluation. The upper parts of right lung lobes were used
to determine the lung wet-to-dry weight ratio and dry
lung-to-body weight ratio. The remaining lobes of the
right lung were stored at -80°C until for determining the
lung hydroxyproline contents.
Lung index measurement
The upper parts of right lungs were excised and weighed
before and after oven desiccation at 80°C for 8 hours to
calculate indexes according to the following formulas:
lung wet-to-dry weight ratio = weight of the whole wet
lung/weight of the whole dry lung; the dry lung-to-body
weight ratio (%) = weight of the whole dry lung/body
weight × 100%.
Histopathological evaluation
After being fixed in 10% formalin for 7 days, the lung tis-
sues were embedded in paraffin. Serial sections (5 μm)
were obtained from the blocks, and three sagittal sections
from each lung, i.e., six sections per animal, were stained
with hematoxylin and eosin (H-E) and Masson's tri-
chrome. The severity of PF was assessed. All of the speci-
mens were numbered randomly and interpreted by an
experimenter blinded to the experimental conditions. Vis-
ual grading of PF was performed by determining the Ash-
croft's score, with some modification [18,19]. Briefly, the
entire fields of each lung section were scanned under an
Olympus microscope (Olympus Optical Co., Ltd.) at a
magnification of × 100, and each field was visually graded
from 0 to 8. Criteria for grading lung fibrosis were as fol-
lows: Grade 0 = normal lung; Grade 1 = minimal fibrous
thickening of alveolar or bronchiolar walls; Grade 3 =
moderate thickening of walls without obvious damage to
lung architecture; Grade 5 = increased fibrosis with defi-
nite damage to lung structure and formation of fibrous
bands or small fibrous masses; Grade 7 = severe distortion
of structure and large fibrous areas; Grade 8 = total fibrous
obliteration of lung fields. After examination of the whole
sections, the mean score of all the fields was taken as the
fibrosis score for each animal. The lung fibrosis severity in
the mice survived on day 30 p.i. was further classified into
4 grades (from no obvious fibrosis to severe fibrosis)
according to fibrosis score ranges as shown in Table 1.
Lung hydroxyproline measurement
Since collagen deposition is a hallmark of fibrosis and col-
lagen contains significant amounts of hydroxyproline,
lung hydroxyproline measurement was used to quantify
the severity of fibrosis in this study [20]. According to the
manufacturer's instructions, hydroxyproline was meas-
ured using the test kit (from Nanjing Jiancheng Bio,
China) to estimate the collagen content of the lung.
Briefly, lung tissues samples from mice were weighed and
hydrolyzed to release hydroxyproline from collagen. Oxi-
dation of the hydroxyproline with chloramines T and the
hydroxyproline chromogen was reacted with paradimeth-
ylaminobenzaldehyde to develop a pink color. Absorb-
ance of colored products was measured at 550 nm
spectrophotometrically and the hydroxyproline contents
of samples were calculated by comparing with the stand-
ards. Data are expressed as micrograms of hydroxyproline
per gram of wet lung weight (μg/g).
Virus titration
Mice were inoculated intranasally with 1 × 101 MID50 of
Chicken/HB/108 viruses (50 μl). Lung tissues were col-
lected on days 1, 3, 5, 6, 8, and 14 p.i. Virus was titrated in
embryonated eggs. Mean viral titers were calculated based
on three mice per group and expressed as log10 EID50 per
milliliter ± SD.
Table 1: The severity of lung fibrosis in H5N1-infected mice survived on day 30 after infection
No obvious fibrosis
(0 ≤ MS§ ≤ 1)
Mild fibrosis
(1 < MS§ ≤ 3)
Moderate fibrosis
(3 < MS§ ≤ 6)
Severe fibrosis









The severity of the pulmonary fibrosis was assessed according to the modified Ashcroft's score as described in methods. § MS means the mean 
score of lung fibrosis for each animal (three sagittal sections from each lung, i.e., six sections per animal).Respiratory Research 2009, 10:107 http://respiratory-research.com/content/10/1/107
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Statistical analysis
Data were analyzed with the Statistical Package for Social
Science (SPSS, Version 13.0) for Windows and results
were expressed as means ± SD. A two-tailed Student t test
was used to determine the differences between groups.
Data were considered to be statistically significant when p
< 0.05.
Results
Clinical and gross pathological observation
H5N1-infected mice presented two stages of clinical signs
over a 30-d time period after viral inoculation. At the
acute stage, the onset and evolution of clinical signs were
as follows: on day 3 p.i., slight altered gait, inactivity, ruf-
fled fur, inappetence and weight loss; at days 6 to 8 p.i.,
more severe inappetence, emaciation, and the visual signs
of labored respirations and respiratory distress. Fifty-six
percent (28 of 50) of H5N1-infected mice died during this
stage, with death peak between days 7 and 8 p.i. The onset
of inappetence and inactivity was correlated with loss of
body weight, which continued to decline until death. The
body temperature slightly declined during the H5N1
infection, and dramatically declined before the mice died.
At the restoration stage, the clinical signs in most survived
animals resolved gradually on days 9 to 14 p.i., and disap-
peared almost completely at days 15 to 30. However, 18%
(4 of 22) of H5N1-infected mice survived the acute stage
but developed late stage disease acceleration as assessed
by the presence of inactivity, weight loss, inappetence and
emaciation. Macroscopical and histopathological evalua-
tions showed that these mice presented severe PF.
Figure 1 shows the changes of body weight and food
intake after H5N1 viral infection. The H5N1 infection in
mice induced an acute reduction in body weight on days
2 to 8 p.i., and caused a greater decrease in body weight
gain on days 10 to 30 p.i. The standard deviations for
body weights in infected mice were much greater than
those in control mice during the restoration period (on
days 10 to 30), indicating the individual differences in the
same group. The similar change was also observed in food
intake. These data suggested that the survived mice com-
promised the quality of life over a 30-d time period after
viral infection.
The H5N1 virus-infected lungs were significantly heavier
than normal lungs (Figure 2A), and showed severe consol-
idation, edema and hepatization with varying degree of
hemorrhage (Figure 2B) on day 7 p.i. On day 30 p.i., some
infected animals developed the massive PF with "flesh"
appearance in one lung but the severe emphysema on the
other (Figure 2C), suggesting that the unilateral lung dys-
function caused by fibrosis was managed to be compen-
sated by the other lung.
Histopathological findings
Histopathological lesions could be subclassified into two
consecutive phases, an initial acute exudative phase and a
final fibrotic phase, although considerable overlap existed
in histological findings between two phases. The his-
topathological changes of lung injury and fibrosis with H-
E and Masson's stain are shown in Figure 3.
At the initial exudative stage, the infected mice presented
typical diffuse pneumonia and the lesions associated with
ARDS on day 7 p.i. There were interstitial edema around
the small blood vessels and adherence of inflammatory
cells to wall of the small vessel (Figure 3A). Alveolar walls
Body weight (a) and food intake (b) after H5N1 infection in mice Figure 1
Body weight (a) and food intake (b) after H5N1 infection in mice. Uninfected control group (Open squares), and 
H5N1 virus-infected group (Solid triangles). * p < 0.05 and ** p < 0.01 for the H5N1-infected group vs. control group. Data are 
presented as means ± SD from 4 mice each group.Respiratory Research 2009, 10:107 http://respiratory-research.com/content/10/1/107
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were thickened, and inflammatory cells infiltrated in the
interstitial and intra-alveolar spaces (Figure 3A). On day
14 p.i., Masson's stain showed that alveolar spaces were
widened and filled with collagen fibers (Figure 3B), indi-
cating that proliferative fibroblastic lesions may develop
in future. Alveolar walls were generally thickened with
infiltration of inflammatory cells and hyperplasia of type
II pneumocytes. Hemorrhage was also observed in inter-
stitium and intra-alveolar space (Figure 3B).
At the final fibrotic stage, the survived mice developed PF
of different severities on day 30 p.i. According to Ash-
croft's method [18,19], severity scores for lung fibrosis in
the survived mice are given in Table 1, which showed that
23% (5 of 22) mice had minimal fibrosis, 32% (7 of 22)
had moderate fibrosis, and 18% (4 of 22) underwent
severe fibrosis. At low power magnification, severe distor-
tion of structure and diffuse fibrous areas were observed
in lung fields (Figure 3C). The severely affected animals
had the typical interstitial fibrosis in lungs, exhibiting
greatly thickened alveolar walls with proliferation of cells
and the accumulation of matrix in interstitial space
bounded by epithelial and endothelial basement mem-
branes (Figure 3D). The diffuse intra-alveolar (airspace)
fibrosis was a common finding at this stage. Large fibrous
areas were seen with an excessive collagen deposition and
cell proliferation in airspaces, which obliterated the alve-
olar spaces, organized lung parenchyma and severely dis-
torted lung (Figure 3D, 3E, 3F and 3G). Bronchiolar wall
was thickened, and numerous fibroblasts proliferated and
protruded into the lumen, leading to bronchiolar stenosis
(Figure 3G, solid arrow). In addition, the focal alveolar
collapse secondary to apposition of the alveolar walls was
observed in some section (Figure 3H), and both alveolar
ectasia and airspace fibrosis were also found in the same
field of lung (Figure 3H).
Lung tissues from control group showed a normal archi-
tecture with opened patterns of alveolar spaces, thin-lined
alveolar septa, only a few alveolar macrophages and min-
imal collagen deposition.
Hydroxyproline content
Hydroxyproline, the amino acid that is found almost
exclusively in collagen, can reflect the collagen deposition
in lungs [20]. Therefore, lung hydroxyproline measure-
ment can provide a direct measurement of the formation
of PF. In this study, lung hydroxyproline contents, as
shown in Figure 4, were measured at days 7, 14, and 30
p.i. On day 7 p.i., H5N1 group showed a significant
decrease of the lung hydroxyproline contents compared
with control animals, which might reflect the develop-
ment of severe lung edema in infected mice. The lung
hydroxyproline levels returned to normal on day 14 p.i.,
and increased by almost two-fold on day 30 p.i. compared
with that in control mice. The change of hydroxyproline
contents was consistent with our histopathological find-
ings which demonstrated the formation of PF on day 30
after infection.
Lung wet-to-dry weight ratio and dry lung-to-body weight 
ratio
Figure 5 shows the effect of H5N1 viral infection on lung
wet-to-dry weight ratios and dry lung-to-body weight
ratios. In H5N1-infected mice, two ratios did not change
obviously on day 3 p.i., but dramatically elevated on day
7 p.i., suggesting the severe edema and inflammatory exu-
dates of the lung. Both ratios of infected mice returned to
control levels on day 14 p.i., indicating that edema and
inflammatory exudates had been reabsorbed. On day 30
p.i., the survived mice showed the significantly decreased
lung wet-to-dry weight ratios but dramatically increased
dry lung-to-body weight ratios, which might be associated
with the formation of PF in H5N1-infected mice.
Macroscopical pathology of lungs after H5N1 infection in mice Figure 2
Macroscopical pathology of lungs after H5N1 infection in mice. (A) Uninfected control lung. (B) H5N1 virus-infected 
lung on day 7 p.i., showing the severe edema and hemorrhage. (C) H5N1 virus-infected lung on day 30 p.i., showing fibrosis one 
side and emphysema on the other side.Respiratory Research 2009, 10:107 http://respiratory-research.com/content/10/1/107
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Replication of H5N1 viruses in mouse lungs
H5N1 viral infection made high titers of viruses in the
lungs on days 5 and 6 p.i., as shown in Figure 6. Peak viral
titer appeared on day 6 p.i., and viruses were below the
detectable level on day 14 p.i.
Discussion
In this report, we focused the development of PF in mice
after intranasal infection with 1 × 101 MID50 of Chicken/
HB/108 H5N1 virus.
The typical ARDS was observed in the early period after
H5N1 viral infection. Most of the infected mice exhibited
clinical signs of respiratory distress with 56% of the mice
died on days 6 to 8 p.i. Macroscopical observation showed
that the infected mice had highly edematous lungs on day
7 p.i., which were also demonstrated by the dramatically
increased lung wet-to-dry weight ratios. At the microscop-
ical level, infected mice exhibited typical diffuse pneumo-
nia and obvious ARDS-associated pathological changes,
including fully developed bronchiolitis, and peribronchi-
olar pneumonia characterized by inflammatory cellular
infiltration, interstitial and alveolar edema, and hemor-
rhage. These data are consistent with our previous studies
[16].
Most infected mice developed PF gradually at late stage.
On day 30 p.i., 18% of the survived mice underwent
severe fibrosis according to Ashcroft's method [18,19].
Typical interstitial and intra-alveolar fibrosis was
observed, with thickened alveolar walls, collapsed alveoli
and large organized areas. Both Intra-alveolar fibrosis and
ectasia were showed simultaneously in the same lung
specimens. Reactive hyperplasia of pneumocytes was
present in organizing phase. Bronchiolar stenosis, result-
ing from the thickened bronchiolar walls with prolifer-
ated fibroblasts, was also found under light microscope.
Moreover, as an important index of fibrosis, the hydroxy-
proline levels increased significantly in H5N1-infected
mice as compared to control group on day 30 p.i., which
showed the deposition of collagen in lungs, and con-
firmed the fibrosis of lungs.
During the restoration period, the clinical signs in most
animals resolved gradually on days 9 to 14 p.i., and disap-
peared almost completely on days 15 to 30. However,
18% (4 of 22) of H5N1-infected mice survived the acute
stage but develop the accelerated disease progression at
late stage, as assessed by the presence of inactivity, weight
loss, inappetence and emaciation. Macroscopical and his-
topathological evaluations showed that these mice pre-
sented severe PF. These data show that the survived
H5N1-infected mice with fibrotic lung severely compro-
mised the quality of life. It is well established that the lung
can be subjected to inflammatory reactions and return to
its pre-inflammatory state [12,13]. If viral pneumonia,
including H5N1 viral infection, causes a more intense
The lung histopathology as shown by H-E and Masson's trichrome staining after H5N1 infection in mice Figure 3 (see previous page)
The lung histopathology as shown by H-E and Masson's trichrome staining after H5N1 infection in mice. On day 
7 p.i., infected mice presented typical diffuse pneumonia with interstitial edema around small blood vessels (Figure 3A, solid 
arrow) and inflammatory cells in thickened alveolar walls (Figure 3A, open arrow). On day 14 p.i., Masson's staining showed 
widened alveolar spaces with collagen fibers (Figure 3B, open arrow), and thickened alveolar walls with infiltration of inflamma-
tory cells and hyperplasia of pneumocytes (Figure 3B, solid arrow). On day 30 p.i., severe distortion of structure and diffuse 
fibrous areas were observed in lung fields (Figure 3C) at low magnification. Some animals displayed typical interstitial fibrosis in 
lungs, characterized by greatly thickened alveolar walls with cell proliferation and matrix accumulation in interstitial space (Fig-
ure 3D, solid arrow). The diffuse intra-alveolar fibrosis was a common finding, with an excessive collagen deposition and cell 
proliferation in airspaces that obliterated the alveolar spaces and severely distorted the structure (Figure 3E and 3F, solid 
arrows; Figure 3D and 3G, open arrows). The thickened bronchiolar walls with proliferated fibroblasts lead to bronchiolar ste-
nosis (Figure 3G, solid arrow). In addition, focal alveolar collapse (Figure 3H, solid arrows) and alveolar ectasia (Figure 3D and 
3H) were observed simultaneously in some sections. Original magnification: A, E, G, H-E × 200; D, F, H-E × 400; C, Masson × 
100; H, Masson × 200; B, Masson × 400.
Hydroxyproline contents of lungs after H5N1 infection in  mice Figure 4
Hydroxyproline contents of lungs after H5N1 infec-
tion in mice. The levels of lung hydroxyproline in H5N1 
virus-infected mice (Solid bars) and control mice (Open bars) 
were determined using test kit, and shown as means ± SD 
from 4 mice each group. * p < 0.05 compared with those in 
control mice.Respiratory Research 2009, 10:107 http://respiratory-research.com/content/10/1/107
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inflammatory process in the lung, the fibrosis, rather than
resolution, might become an inevitable outcome. During
experiments, we found no secondary bacterial infection,
and titers of viruses in the lungs were below the detectable
levels on day 14 p.i. Our data is likely to reflect the clinical
and pathological evolution from ARDS to fibrosis in lungs
subsequently to H5N1 infection in mice.
For human, fibrosis of the lung is correlated with respira-
tory failure and an increased risk of death [11,21]. Several
postmortem reports on patients with H5NI influenza
have demonstrated the presence of organizing diffuse
alveolar damage with interstitial fibrosis [22]. So, under
the pressure of pandemic human-avian influenza in the
near future, we must be prepared to prevent the spread of
this virus and find effective method to reverse the relent-
less progress of PF induced by H5N1 viral infection. Our
research may provide a valuable mouse model to study
the development of this disease and to search for treat-
ment of the human H5N1 influenza.
At present, the pathogenesis of PF is not fully understood.
Some studies showed that the cytokines, such as trans-
forming growth factor-β (TGF-β), interleukin-10 (IL-10),
and platelet-derived growth factor (PDGF), appeared to
have an important role in the control of fibroblast activity
in vitro, and have been implicated in the pathogenesis of
PF [23,24]. PF is difficult to treat clinically and few drugs
can be useful. Corticosteroid therapy like dexamethasone
is the current first-line choice to prevent this disease
because of its anti-inflammatory effects [25]. Laboratory
studies showed that corticosteroids might prevent the col-
lagen overexpression and decrease the up-regulated
cytokines including TGF-β in bleomycin-induced PF
model [26,27]. Our further study will use the mouse
model to focus on the role of cytokines in pathogenesis of
PF and the effect of some drugs on PF induced by H5N1
virus.
Conclusion
Our findings show that H5N1-infected mice develop typ-
ical PF during restoration period as a result of ARDS,
which will contribute to the investigation of fibrogenesis
and potential therapeutic intervention in human H5N1
disease.
Lung wet-to-dry weight ratios (a) and dry lung-to-body weight ratios (b) after H5N1 infection in mice Figure 5
Lung wet-to-dry weight ratios (a) and dry lung-to-body weight ratios (b) after H5N1 infection in mice. Unin-
fected control group (Open bars), and H5N1 virus-infected group (Solid bars). * p < 0.05 for the H5N1 virus-infected group vs. 
control group. Values are presented as means ± SD from 4 mice each group.
Replication of H5N1 virus in mouse lungs Figure 6
Replication of H5N1 virus in mouse lungs. Mice were 
inoculated intranasally with 1 × 101 MID50 of Chicken/HB/108 
virus. Viruses were titrated in embryonated eggs. Mean viral 
titers (Solid bars) were calculated based on three mice per 
group.Respiratory Research 2009, 10:107 http://respiratory-research.com/content/10/1/107
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